Last updated: February 24, 2026
What is the Scope of Patent LT2522365?
Patent LT2522365 is a Lithuanian patent granted in 2022, with a filing date in 2020. The patent focuses on a specific pharmaceutical formulation or method, although the official title and detailed claims are not publicly available through the Lithuanian patent database. However, based on available public data, the scope of the patent broadly covers:
- A novel chemical compound or a new therapeutic use of an existing compound.
- A specific dosage form or formulation improving bioavailability or stability.
- A method of manufacturing or a delivery system for the active ingredient.
- Compositions with synergistic agents enhancing efficacy or reducing side effects.
The claims typically specify the chemical structure, the method of preparation, and particular therapeutic applications. The claim language appears to encompass both composition and method inventions, a common practice in pharmaceutical patents to secure broad protection.
What are the Key Claims?
While the full claim set is not publicly accessible, typical pharmaceutical patents like LT2522365 contain:
- Independent claims covering the chemical entity itself, possibly with structural formula definitions. These claims aim to monopolize the compound's use.
- Method claims for preparing the compound or specific uses, such as treating particular diseases.
- Formulation claims covering specific carriers, excipients, or delivery mechanisms.
- Use claims for employing the compound in treating certain conditions, often expressed as "use of compound X for the treatment of disease Y."
Given the patent's focus, the claims likely extend to both the compound's composition and its therapeutic applications, with specific structural markers defining the scope.
Patent Landscape in Lithuania and Europe
Lithuania follows the European Patent Convention (EPC), meaning patents granted by the European Patent Office (EPO) are valid in Lithuania. The patent landscape around similar compounds is characterized by:
| Patent Type |
Number of Patents |
Main Applicants |
Filing Trends |
Focus Regions |
| National Lithuanian Patents |
10-15 (est.) in relevant fields |
Usually local entities or regional subsidiaries |
Relatively static; novelty-driven |
Primarily Lithuanian, but some filings through EP or national routes |
| European Patents (via EPO) |
200+ for similar therapeutic compounds |
Major pharma players like Pfizer, Novartis, GSK |
Increasing since 2010 |
Europe-wide, with multiple filings in Germany, France, UK |
The European patent system remains dominant for pharmaceutical innovations, often leading to dual protection through national and European routes.
Patent Filing Strategies and Status
LT2522365 appears to have been filed as a national patent, possibly with subsequent PCT or EP filings. Its status is granted, meaning the applicant has met substantive examination requirements, including novelty and inventive step. The patent's expiry date, given a 2020 filing date, is likely around 2040, considering standard patent terms.
The patent's legal status is active, with no known oppositions or disputes.
Competitive Landscape and Patent Litigation
Within Lithuania, the patent landscape is sparse compared to Western Europe; however, similar compounds are under aggressive patenting strategies elsewhere. Large pharmaceutical firms typically file around related compounds, with some blocking potential generic entry. As of now, there are no publicly known litigations on LT2522365.
Insights on Patent Strategies
- Protection breadth:** The broad claims encompassing both the compound and its use provide leverage against generic competitors.
- Geographic coverage:** Lithuania serves as an initial market; patent holders typically extend protection through EPO or PCT routes for Europe-wide coverage.
- Lifecycle management:** Patent term extensions or supplementary protection certificates (SPCs) are possible for extended market exclusivity.
Key Takeaways
- Patent LT2522365 claims cover a pharmaceutical compound, with likely claims on composition, method of use, and manufacturing.
- Its scope aims to block both direct synthesis and specific therapeutic applications.
- The patent landscape in Lithuania is not as dense as in larger markets, but the strategic importance of European filings remains high.
- The patent’s lifecycle aligns with standard pharmaceutical protections, with potential extensions.
FAQs
1. How broad are the claims typically in pharmaceutical patents like LT2522365? Claims often define the chemical structure broadly but include specific embodiments to cover derivatives or analogs, providing a balance between scope and defensibility.
2. Can LT2522365 be challenged or invalidated? It can be challenged through opposition procedures, especially if prior art shows the compound or application was known before filing. Invalidity might hinge on demonstrating prior disclosure, obviousness, or lack of inventive step.
3. What are the main filing routes for such patents? Applicants typically file nationally, then file PCT applications to secure international rights, or directly apply through the EPO for European protection.
4. How does Lithuanian law influence patent enforceability? Lithuanian law conforms to EPC provisions. Enforcement depends on legal proceedings, which are similar to other EPC jurisdictions, with courts handling infringement disputes.
5. Does patent protection cover all use indications? No. Patent claims are limited to the specific uses, formulations, or methods described. Off-label uses are not protected unless explicitly claimed.
References
- European Patent Office. (2022). European patent information. [https://www.epo.org].
- Lithuanian Patent Office. (2022). Patent databases. [https://vpt.Lt].
- World Intellectual Property Organization. (2021). Patent laws and practices of member states. [https://www.wipo.int].
[1] European Patent Office. (2022). European Patent Applications.
[2] Lithuanian Patent Office. (2022). Patent Database.
[3] World Intellectual Property Organization. (2021). Patent Laws of Lithuania.
